

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB 3235-Number: 0104 Estimated average burden hours per response... 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)							
1. Name and Address of Reporting	2. Date of Event Requiring	3. Issuer Nan	ne and Ticker	or Trad	ling Symbol		
Person [*]	Statement	Cellectar Biosciences, Inc. [CLRB]					
Pedder Simon	(Month/Day/Year) 08/14/2014						
(Last) (First) (Middle)	00/14/2014		ip of Reporting	g	5. If Amendment, Date Original		
C/O CELLECTAR		Person(s) to Issuer			Filed(Month/Day/Year)		
BIOSCIENCES, INC., 3301		(Check all applicable)					
AGRICULTURE DRIVE		X_ Director X Officer (g	10% O other (wner specify			
(Street) MADISON, WI 53716		title below) Presic	below) lent and CEO		6. Individual or Joint/Group Filing(Check Applicable Line) X Form filed by One Reporting Person		
WADISON, WI 55710					Form filed by More than One Reporting Person		
(City) (State) (Zip)	Table I - Non-Derivative Securities Beneficially Owned						
1.Title of Security	2. Amount of	f Securities	3.	4. Nat	ure of Indirect Beneficial		
(Instr. 4)	Beneficially	Owned	Ownership	Owner	rship		
	(Instr. 4)		Form: Direct	(Instr.	5)		
			(D) or				
			Indirect (I)				
			(Instr. 5)				

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1473 (7-02)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

Table II - Derivative Securities Defendiary Owned (e.g., puts, cars, warrants, options, convertible securities)								
1. Title of Derivative Security (Instr. 4)	Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		or Exercise	Ownership	6. Nature of Indirect Beneficial Ownership (Instr. 5)	
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Security Dire or In (I)	Security: Direct (D) or Indirect (I) (Instr. 5)		
Employee Stock Option (right to buy)	<u>(1)</u>	10/04/2023	Common Stock	168,000	\$ 6.6	D		
Employee Stock Option (right to buy)	<u>(1)</u>	10/04/2023	Common Stock	96,278	\$ 15	D		

Reporting Owners

Penarting Owner Name / Address		Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
Pedder Simon C/O CELLECTAR BIOSCIENCES, INC. 3301 AGRICULTURE DRIVE MADISON, WI 53716	X		President and CEO				

Signatures

/s/ Paul Bork, attorney-in-fact for Simon Pedder

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Option vests in equal quarterly increments over a period of three years from the date of grant. Option expires on the tenth anniversary of the date of grant.

Remarks:

Exhibit 24 - Power of Attorney

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

CONFIRMING STATEMENT

This Statement confirms that the undersigned has authorized and designated Paul Bork, Matthew Eckert, Chad Kolean and Christina Blakley, each acting singly, to execute and file on the undersigned's behalf a Form ID and all Forms 3, 4, and 5 (including any amendments thereto) that the undersigned may be required to file with the U.S. Securities and Exchange Commission as a result of the undersigned's ownership of or transactions in securities of Cellectar Biosciences, Inc. The authority of Paul Bork, Matthew Eckert, Chad Kolean and Christina Blakley under this Statement shall continue until the undersigned is no longer required to file Forms 3, 4, and 5 with regard to the undersigned's ownership of or transactions in securities of Cellectar Biosciences, Inc. unless earlier revoked in writing. The undersigned acknowledges that Paul Bork, Matthew Eckert, Chad Kolean and Christina Blakley are not assuming any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934.

This Statement revokes the authority of any person named in any prior confirming statement relating to the undersigned's filing obligations with respect to securities of Cellectar Biosciences, Inc. who is not named herein, and this Statement replaces and supersedes any such prior confirming statement.

Dated:

August 8, 2014

Signed: /s/ Simon Pedder

Print Name: Simon Pedder